Form 4: Ultragenyx Director Narachi Acquires Shares and Options

Director Michael Narachi acquired shares and options in Ultragenyx Pharmaceutical Inc. on May 15, 2025, according to a Form 4 filing.

Summary

• Michael Narachi, a director at Ultragenyx Pharmaceutical Inc., reported changes in beneficial ownership on May 19, 2025.
• On May 15, 2025, Narachi acquired 5,740 shares of common stock through Restricted Stock Units (RSUs) at $0, and 10,787 stock options with an exercise price of $34.84.
• The RSUs and options vest fully on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.
• Following these transactions, Narachi directly owns 32,690 shares of common stock and 10,787 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions, which can be interpreted as a sign of confidence, but it's not overwhelmingly positive or negative.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The RSUs and options vest on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's stock.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive signal.

Key Dates

Keywords

Ultragenyx, Director, Narachi, Stock Options, RSUs, Form 4, Beneficial Ownership, RARE